Online inquiry

IVTScrip™ mRNA-Anti-LAG3, BMS-986016(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4626MR)

This product GTTS-WQ4626MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets LAG3 gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_002286.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3902
UniProt ID P18627
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LAG3, BMS-986016(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ4626MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7512MR IVTScrip™ mRNA-Anti-HBV, GC-1102(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GC-1102
GTTS-WQ10954MR IVTScrip™ mRNA-Anti-HAVCR2, MBG-453(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MBG-453
GTTS-WQ10604MR IVTScrip™ mRNA-Anti-PDCD1, LY3300054(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LY3300054
GTTS-WQ9764MR IVTScrip™ mRNA-Anti-PDCD1, JS001(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA JS001
GTTS-WQ1125MR IVTScrip™ mRNA-Anti-CD40, ABBV-927(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ABBV-927
GTTS-WQ5754MR IVTScrip™ mRNA-Anti-EGFR, CetuxiMab-GEX(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CetuxiMab-GEX
GTTS-WQ8991MR IVTScrip™ mRNA-Anti-IL13, IMA-638(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IMA-638
GTTS-WQ13599MR IVTScrip™ mRNA-Anti-APP, R1450(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA R1450
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW